Tags : Janssen Biotech

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More

Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study

Shots: The P-III MMY3021 study involves assessing of daratumumab (1800mg, SC) + lenalidomide vs lenalidomide as monothx. in 214 newly diagnosed multiple myeloma patients who are MRD + after autologous stem cell transplant (ASCT) with no prior anti-CD38 exposure In H1’19 the companies plan to initiate the P-III MMY3021 study for daratumumab with 1EPs as […]Read More